Future Fields uses fruit flies to scale hard-to-express protein production

Hard-to-express proteins are where recombinant manufacturing gets expensive, slow, and frustrating, especially when the target has to be correctly folded, glycosylated, and clean enough for cell therapy, IVD, or biopharma use. Future Fields is trying to attack that bottleneck with a whole-insect system built on Drosophila melanogaster, a move that sounds unconventional until you look at the economics of proteins that do not behave in E. coli, yeast, or even mammalian cells.

Why the bottleneck matters

The standard protein-production stack still leans heavily on microbial tanks and mammalian bioreactors, but those systems are not equally good at every target. Simple proteins can be made cheaply in microbes; the problems start when a protein is fragile, highly modified, or difficult to express at useful yields. That is the market gap Future Fields is trying to fill with EntoEngine, its synthetic biology platform that uses fruit flies as a multi-cellular, whole-insect bioreactor.

The pitch is not just novelty. The company says EntoEngine can produce glycosylated proteins without immunogenic alpha1,3-fucosylation, which matters because glycosylation is often the difference between a protein that works and one that fails in a therapeutic setting. Future Fields is also aiming at a wide range of targets, from difficult-to-express proteins to basic fibroblast growth factor, which is a useful signal that the platform is meant to handle both premium, finicky molecules and more routine recombinant products.

How the fly-based system works

Future Fields says EntoEngine relies on stable integration of a gene of interest into the fruit fly genome, then produces protein by harvesting and purifying it from fly biomass. That is a very different manufacturing logic from a stainless-steel fermenter full of yeast or bacteria: instead of forcing a single-celled system to carry the whole burden, the company is using a living animal as the production chassis.

The company, founded in 2018 and based in Edmonton, Alberta, describes EntoEngine as the world’s first synthetic biology system to use fruit flies for recombinant protein production. Its scaling claim is equally aggressive: Future Fields says the platform is modular and fast, and can produce micrograms to grams of recombinant protein daily. If that holds up outside company demos, it is exactly the sort of throughput profile that would matter to teams running iterative discovery, preclinical work, or smaller commercial runs where speed matters as much as raw volume.

Where fruit flies could beat the usual suspects

The strongest case for fruit flies is not that they replace every other system. It is that they may be better for a narrow but painful slice of the market where microbial systems underperform and mammalian systems are expensive. If you need a protein with more complex biology than bacteria can handle, but you do not want the cost structure of large mammalian infrastructure, a fly-based platform starts to look interesting.

Future Fields frames the system as a sustainable alternative as well. The company says its biomanufacturing approach uses less water and energy, and takes up less land than traditional recombinant protein production methods. That matters because protein manufacturing is not just a scientific problem; it is a capital and utilities problem. The more a platform can compress facility footprint, power demand, and water use, the more attractive it becomes for smaller operators that cannot justify a giant steel-tank buildout.

That point comes through in the company’s commercial messaging. CEO Matt Anderson-Baron has said small and mid-sized biopharma companies want flexible, lower-cost custom protein services that are eco-friendly and can bring therapeutics to market faster. That customer profile makes sense for a system that promises rapid modular scaling rather than a huge up-front plant.

What Instar 1.0 says about the company’s ambitions

Future Fields is not presenting this as a bench-only experiment. In November 2024, it launched Instar 1.0, a 6,000-square-foot biofactory in downtown Edmonton designed to scale production around the EntoEngine platform. The company said the facility would employ more than 20 technicians, chemists, and biomolecular specialists, and claimed it has 30 times the output of conventional protein technology.

That is a serious move toward industrialization, not just platform science. A 6,000-square-foot factory is still small by biopharma standards, but it is big enough to signal that the company wants to prove a repeatable manufacturing model, not merely publish an unusual expression system. The downtown Edmonton location also matters because it places the platform in a real operating environment with a workforce, workflows, and downstream purification demands, not just a research greenhouse.

The money, the advisers, and the credibility test

Future Fields has been building its story with capital and name recognition. On June 17, 2025, it announced an oversubscribed $8 million Series A to expand commercial traction across agriculture, food, and biopharma markets. Earlier company materials said it had raised $15.1 million CAD to build out capacity. That funding trail suggests the company is trying to move beyond proof-of-concept into a broader service business.

The advisory board additions reinforce that ambition. Nobel Prize laureate Michael Houghton joined in August 2022, and SynBioBeta founder John Cumbers joined in May 2023. Those names do not prove manufacturing economics, but they do signal that Future Fields is working to look more like a serious synthetic biology platform company than a one-off biohacking story.

Where the skepticism still lives

The obvious caution is that a novel host does not automatically become a dominant manufacturing platform. Future Fields says it can produce glycosylated proteins without immunogenic alpha1,3-fucosylation, but the real question is how consistent that quality remains across batches, target classes, and scale-up conditions. Any platform claiming to handle everything from difficult proteins to basic fibroblast growth factor has to show that yield, purity, and post-translational fidelity stay intact when the commercial pressure rises.

There is also a category question. Fruit flies may be a credible solution for certain hard-to-express proteins, especially where mammalian production is too costly and microbes are not enough. But for the platform to move from intriguing to indispensable, it has to prove that its economics hold at the gram scale, that purification from fly biomass is practical, and that customers can trust the output for regulated applications.

For now, EntoEngine looks less like a lab curiosity than a platform trying to break into the real market at the exact point where protein manufacturing hurts most. If Future Fields can keep the quality claims intact while lowering the cost and complexity of difficult proteins, fruit flies may earn a place in the manufacturing toolbox. If not, they will remain one of the more inventive detours in the search for better bioreactors.